RxDoctor Payments DataLook up a doctor →

Catherine Lowe, MD

Interventional Cardiology · Jackson, MSNPI 1194104265

Payments from drug & device makers

$20,744in general payments, 2019–2025

Across 414 payments — averaging $50.11 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$10K
  • Abiomed$3K
  • Boston Scientific$2K
  • Novartis$876
  • Inari Medical, Inc.$468
  • Abbott$417
  • plus $4K from 35 others

What the payments were for

  • Travel & lodging$9,17544%
  • Food & beverage$11,42955%
  • Education$1401%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$20,744 in reported general payments places this provider in the 70th percentile of 65 interventional cardiology providers in Mississippi.

See all interventional cardiology providers in Mississippi

Medicare billing

Part B allowed, 2024
$416,795
Medicare patients
1,149
Services billed
6,562

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan171$149,229
EliquisApixaban221$138,566
JardianceEmpagliflozin87$86,946
BrilintaTicagrelor144$72,904
FarxigaDapagliflozin Propanediol100$61,255
XareltoRivaroxaban48$51,094
Repatha SureclickEvolocumab37$20,194
Praluent PenAlirocumab11$5,137
Rosuvastatin Calcium469$3,096
Metoprolol Succinate369$2,937
ClopidogrelClopidogrel Bisulfate330$2,729
Atorvastatin Calcium383$2,054
Losartan Potassium237$1,310
Amiodarone Hcl75$1,287
Ezetimibe95$1,007

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$876$149,229171 claims
PfizerEliquis$310$138,566221 claims
AstraZenecaBrilinta, Farxiga$151$134,159244 claims
Boehringer IngelheimJardiance$340$86,94687 claims
Johnson & JohnsonXarelto$195$51,09448 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 65 interventional cardiology providers in Mississippi.

Other interventional cardiology in Jackson

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →